Pressroom: Press Releases


New Drug Combination Slows Tumor Growth For Recurrent Ovarian Cancer

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III “OCEANS” trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

June 4, 2011
Tumors In Majority Of Patients With Advanced Lung Cancer Found To Have Genetic Mutations That Can Be Treated With Targeted Therapies

A new study detected one of ten such mutations in 54 percent of the 516 lung cancer patients tested at diagnosis. The results enabled doctors to select the most appropriate drug designed to block the identified mutation and choose other treatment options for those patients whose tumors did not have a mutation.

June 4, 2011
Drug Shown To Significantly Improve Survival In Men With Metastatic Prostate Cancer While Exploring A Potential Biomarker To Measure Treatment Response

The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are exploring a potential biomarker of response to treatment in general.

June 4, 2011
Drug Shown to Improve Overall Survival in Patients with Metastatic Prostate Cancer

An international, multi-center study has found that a recently FDA-approved drug called abiraterone acetate significantly improves overall survival in men with metastatic prostate cancer by more than 34 percent. Researchers at Memorial Sloan Kettering Cancer Center, the Institute of Cancer Research and the Royal Marsden Hospital in the UK as well as other cancer centers around the world published the findings in the May 26, 2011, issue of The New England Journal of Medicine.

May 25, 2011
Blood Test Given Earlier Than Recommended Predicts Long-Term Risk of Death from Prostate Cancer and Suggests Annual PSA Testing for Most Men is Unnecessary

A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center.

May 19, 2011
Novel Immunotherapy Drug Receives FDA Approval for the Treatment of Metastatic Melanoma

The US Food and Drug Administration announced today that the drug ipilimumab (brand name Yervoy) has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.

March 25, 2011
Change in PSA Level Does Not Predict Prostate Cancer

Researchers at Memorial Sloan Kettering Cancer Center have found that change in PSA levels over time - known as PSA velocity - is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.

February 24, 2011
Memorial Sloan Kettering Cancer Center Plans to Open Outpatient Cancer Facility in Westchester

Memorial Sloan Kettering Cancer Center has filed an application with the New York State Department of Health to open a freestanding outpatient facility in Harrison, New York. If approved, the new 114,000-square-foot treatment facility will offer area residents the most advanced cancer care services, closer to home.

January 31, 2011
Novel Cancer-Targeting Investigational Nanoparticle Receives FDA IND Approval for First-In-Human Trial

Researchers at Memorial Sloan Kettering Cancer Center’s Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.

January 31, 2011


Novel Genetic Mutation that Causes the Most Common form of Eye Cancer Discovered

An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of tumor samples taken from patients with uveal melanoma.

November 17, 2010
Genetic Variants May Affect the Risk of Breast Cancer in Women with BRCA2 Mutations

An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer.

October 28, 2010
New Way of Expanding Cancer Screening for Minority Women

Minority patients have a significantly decreased survival from colon cancer compared to white patients, most often as a result of a late diagnosis. To help address this problem, a team of healthcare professionals at Memorial Sloan Kettering Cancer Center has identified an efficient way to increase minority access to lifesaving colorectal cancer screening (CRCS) in communities where multiple barriers to preventive care exist.

October 25, 2010
Researchers Discover Genetic Changes That Make Some Forms of Brain Cancer More Aggressive Than Others

A multi-institutional team led by investigators from Memorial Sloan Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies.

October 1, 2010
Blood Test Accurately Predicts Death from Prostate Cancer up to 25 Years in Advance

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings were published today online in the British Medical Journal.

September 14, 2010
Innovative Outpatient Chemotherapy Center to Open in Brooklyn

Memorial Sloan Kettering Cancer Center (MSKCC) today celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health. The 7,745-square-foot facility, called the Brooklyn Infusion Center, will provide leading-edge chemotherapy services to current MSKCC patients who live in or near Brooklyn - which amounts to more than 15 percent of MSKCC’s patients currently being treated in Manhattan.

September 13, 2010
New Targeted Therapy for Advanced Melanoma Associated with 80 Percent Response Rate

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine.

August 25, 2010
Craig Thompson Named President of Memorial Sloan Kettering Cancer Center

Craig B. Thompson, MD, has been named the new President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center effective November 2, 2010. His appointment concludes a search that began in January 2010.

August 10, 2010
Newly Developed Prediction Tool Helps Estimate Local Recurrence in Patients with Non-invasive Breast Cancer

The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. In an attempt to help physicians and patients weigh the risks and benefits of the available options, researchers from Memorial Sloan Kettering Cancer Center (MSKCC) are reporting in the Journal of Clinical Oncology on the development of a new prediction tool that calculates a patient’s individualized risk for recurrence five and ten years after surgery.

July 13, 2010
New Cancer Diagnostic and Treatment Facility Opens

Image-guided interventions are revolutionizing cancer diagnosis and treatment. MSKCC’s new Center for Image-Guided Intervention (CIGI), which opened in June, offers cancer patients the most advanced, minimally invasive diagnostic and treatment options in a unique multidisciplinary setting designed to foster rapid innovations in cancer care.

July 7, 2010
Large-Scale Genomic Analysis of Prostate Cancer Unveiled

A unique collaboration among physician-scientists at Memorial Sloan Kettering Cancer Center has yielded the most comprehensive genomic analysis of prostate cancer to date. The study, published in the journal Cancer Cell, provides a previously unavailable genomic analysis whose scope and size offers new insight leading to more effective diagnostic tests as well as future treatment options for prostate cancer patients.

June 24, 2010
Syndicate content